Therefore, based on these promising preclinical and clinical data, several ongoing studies of PI3K inhibitors in combination with hormonal therapy as a strategy to overcome hormonal therapy-resistant breast cancer are being conducted, including the BYLieve study (NCT03056755) and the SAFIR study (NCT02734615, NCT03386162, NCT01870505). Here, PIK3CD is linked to breast carcinoma.